Leverage the Power of the Proteome to Drug the Undruggable

Utilize High-Throughput Proteomics to Accelerate Hit Screening, Target Validation & Lead Optimization for Smarter & Faster Drug Development

Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2027 event, please get in touch at info@hansonwade.com

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable.

The Proteomics-Based Drug Discovery Summit is the premier industry event dedicated to harnessing the full power of proteomics across drug discovery pipelines. Designed for scientific innovators like you, explore how next-generation proteomic platforms are accelerating understanding of pathology, unveiling novel drug targets, and transforming hit-to-lead development.

With a special focus on optimizing proteomics instruments to balance throughput and sensitivity, automating sample processing, unveiling hidden disease mechanisms with PTM analysis, and defining gold-standard analysis methodologies; this forum is ideal for proteomics leaders aiming to expand the druggable proteome and achieve therapeutic options for diseases with unmet need.

As proteomics continues to evolve, make headlines, and revolutionize therapeutic development, unite with Directors, Vice President and Experts in Proteomics, Chemical Biology, Mass Spectrometry and Bioinformatics to achieve protein level insights to advance your own discovery pipeline.

An exceptional platform that brought together industry experts to share their experiences and discuss the latest trends and challenges in the field

Xudong Wang, Senior Scientist, Monte Rosa Therapeutics

Monte Rosa teaser

A valuable opportunity to network with leading proteomics experts, exchange ideas across diverse research areas, and stay current on emerging technologies driving the field

Executive Director, Aethon Therapeutics

Aethon Therapeutics, Inc. logo

The program was well organized, and each presentation was very educational. The networking sessions were also well thought out

Senior Director, Daiichi Sankyo

Daiichi-Sankyo

Confirmed Attendees Included

Acrivon
Aethon
Arvinas
BluePrint Medicines
Dunad Therapeutics
Eisai
Frontier Medicines
Johnson & Johnson Innovative Medicine
Merck
Profound Therapeutics
Sanofi

Explore the 2026 Event Guide

  • Hear from the 100% brand-new speakers that joined us in 2026, sharing case studies on mass spectrometry, chemoproteomics, single-cell, and spatial proteomics platforms
  • Uncover drug discovery applications across bispecifics, covalent small molecules, TPD, and more
  • Review real-life examples on balancing throughput, coverage, and sensitivity of proteomic workflows
Brochure cover for Proteomics Based Drug Discovery Summit

What the 2026 Summit Offered

70+

Biopharma Leaders Unlocking the Power of Proteomics

24+

Brand-New Speakers Pioneering Proteomics Across Drug Discovery

20+

Innovative Biopharma Companies & Academic Institutions Presenting

7+

Hours of Dedicated Networking Time

1

Interactive, Deep-Dive Workshops

1

Scientific Poster Session

2026 Official Partners

Brochure cover for Proteomics Based Drug Discovery Summit
Quick Download
Explore The Agenda
Explore the 2026 Agenda

Hear the latest breakthroughs in throughput, coverage, and sensitivity of proteomics methodologies, uncover data-driven presentations, and engage in panel discussions on translating large-scale proteomics data into meaningful drug discovery conclusions.

Partner with Us
Partner With Us

Position yourself alongside other proteomics, mass spectrometry and data analysis solution providers, demonstrating your capabilities and increasing your brand awareness to a room full of proteomics decision makers.

Join Pharma Experts
Join Biopharma Experts

Be part of cutting-edge discussions with fellow proteomics pioneers to transform drug discovery across a range of modalities, whether you’re working on TPD, ADCs, small molecules, or beyond.